[go: up one dir, main page]

FR2702150B1 - Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA. - Google Patents

Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA.

Info

Publication number
FR2702150B1
FR2702150B1 FR9302439A FR9302439A FR2702150B1 FR 2702150 B1 FR2702150 B1 FR 2702150B1 FR 9302439 A FR9302439 A FR 9302439A FR 9302439 A FR9302439 A FR 9302439A FR 2702150 B1 FR2702150 B1 FR 2702150B1
Authority
FR
France
Prior art keywords
benzothiadiazine
application
receptor antagonists
nmda receptor
dioxide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9302439A
Other languages
English (en)
Other versions
FR2702150A1 (fr
Inventor
Francois Audiau
Patrick Jimonet
Serge Mignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9302439A priority Critical patent/FR2702150B1/fr
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to PL94310439A priority patent/PL310439A1/xx
Priority to EP94908373A priority patent/EP0687178A1/fr
Priority to HU9502572A priority patent/HU9502572D0/hu
Priority to CA002153951A priority patent/CA2153951A1/fr
Priority to AU61436/94A priority patent/AU6143694A/en
Priority to PCT/FR1994/000207 priority patent/WO1994020109A1/fr
Priority to JP6519646A priority patent/JPH08507303A/ja
Priority to IL10878494A priority patent/IL108784A0/xx
Publication of FR2702150A1 publication Critical patent/FR2702150A1/fr
Application granted granted Critical
Publication of FR2702150B1 publication Critical patent/FR2702150B1/fr
Priority to NO953387A priority patent/NO953387L/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
FR9302439A 1993-03-03 1993-03-03 Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA. Expired - Fee Related FR2702150B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR9302439A FR2702150B1 (fr) 1993-03-03 1993-03-03 Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA.
JP6519646A JPH08507303A (ja) 1993-03-03 1994-02-25 非競合的ｎｍｄａ受容体アンタゴニストとしての２ｈ−１，２，４−ベンゾチアジアジン３（４ｈ）−オン１，１ジオキシド誘導体の使用
HU9502572A HU9502572D0 (en) 1993-03-03 1994-02-25 Use of 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxide derivatives as non-competitive nmda receptor antagonists
CA002153951A CA2153951A1 (fr) 1993-03-03 1994-02-25 Application de derives de 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxyde comme antagonistes non competitifs du recepteur nmda
AU61436/94A AU6143694A (en) 1993-03-03 1994-02-25 Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists
PCT/FR1994/000207 WO1994020109A1 (fr) 1993-03-03 1994-02-25 Application de derives de 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxyde comme antagonistes non competitifs du recepteur nmda
PL94310439A PL310439A1 (en) 1993-03-03 1994-02-25 Application of derivatives of 2-h-1,2,4-benzothiazin-3/4h/-one 1,1-dioxide as noncompetitive antagonists of nmda receptor
EP94908373A EP0687178A1 (fr) 1993-03-03 1994-02-25 Application de derives de 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxyde comme antagonistes non competitifs du recepteur nmda
IL10878494A IL108784A0 (en) 1993-03-03 1994-02-28 Use of 2h-1,2,4-benzothiadiazin-3(4h)-one 1,1-dioxide derivatives as noncompetitive antagonists of the mmda receptor
NO953387A NO953387L (no) 1993-03-03 1995-08-29 Anvendelsen av 2H-1,2,4-benzotiadiazin 3 (4H)-on 1,1-dioksydderivater som ikke-kompetitive NMDA-reseptor-antagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9302439A FR2702150B1 (fr) 1993-03-03 1993-03-03 Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA.

Publications (2)

Publication Number Publication Date
FR2702150A1 FR2702150A1 (fr) 1994-09-09
FR2702150B1 true FR2702150B1 (fr) 1995-04-07

Family

ID=9444603

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9302439A Expired - Fee Related FR2702150B1 (fr) 1993-03-03 1993-03-03 Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA.

Country Status (10)

Country Link
EP (1) EP0687178A1 (fr)
JP (1) JPH08507303A (fr)
AU (1) AU6143694A (fr)
CA (1) CA2153951A1 (fr)
FR (1) FR2702150B1 (fr)
HU (1) HU9502572D0 (fr)
IL (1) IL108784A0 (fr)
NO (1) NO953387L (fr)
PL (1) PL310439A1 (fr)
WO (1) WO1994020109A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
EP2091948B1 (fr) 2006-11-30 2012-04-18 Probiodrug AG Nouveaux inhibiteurs de glutaminylcyclase
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (fr) 2011-03-16 2016-02-03 Probiodrug AG Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975925A (en) * 1961-02-21 1964-11-25 Scherico Ltd 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US4716161A (en) * 1984-04-17 1987-12-29 Mitsubishi Chemical Industries Limited Phenylpiperazine derivatives and their acid addition salts
FR2675801A1 (fr) * 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, leur preparation et les medicaments les contenant.
WO1993021170A1 (fr) * 1992-04-15 1993-10-28 Rhone-Poulenc Rorer S.A. Derives d'acide 3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxyde-3-carboxylique, leur preparation et les medicaments les contenant
FR2690160A1 (fr) * 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.

Also Published As

Publication number Publication date
PL310439A1 (en) 1995-12-11
NO953387D0 (no) 1995-08-29
NO953387L (no) 1995-08-29
AU6143694A (en) 1994-09-26
IL108784A0 (en) 1994-06-24
WO1994020109A1 (fr) 1994-09-15
HU9502572D0 (en) 1995-11-28
EP0687178A1 (fr) 1995-12-20
CA2153951A1 (fr) 1994-09-15
JPH08507303A (ja) 1996-08-06
FR2702150A1 (fr) 1994-09-09

Similar Documents

Publication Publication Date Title
EE9800171A (et) 3-pürasoolkarboksamiidi derivaadid, mis omavad afiinsust kannabinoidretseptori suhtes
FI970328A0 (fi) Heterosykliset yhdisteet, jotka ovat käyttökelpoisia allosteerisinä effektoreina muskariinireseptoreissa
ID28695A (id) TURUNAN-TURUNAN BENZO (b) TIEPIN 1,1-DIOKSIDA, PROSES PENYIAPAN, SEDIAAN FARMASI YANG MENGANDUNG SENYAWA-SENYAWA INI, DAN PENGGUNAANNYA
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
FI953748L (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
EP1066262A4 (fr) Agents anorexigenes d'imidazolone: derives acycliques i
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
FR2702150B1 (fr) Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA.
BR9609830A (pt) Processos para a preparação de (S)-4-([3-]2-(Dimetilamino)etil]-1H-indola-5il]metilü-2-oxazolidinona para a purificação de (S)-4-ä[3-(dimetilamino)etil]-1H-indola-5-il].metilü-2-oxazolidinona e para preparação de um composto composto intermediário e uso de um intermediário
FR14C0044I2 (fr) Derives de 3-(2-oxo- 1,3']bipyrrolidinyl-3-ylidenemethyl)-cephemes
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
NO20002036D0 (no) Cyklopentenderivater nyttig som antagonister for motilinreseptoren
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
FR2708201B1 (fr) Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
MA26543A1 (fr) Derives de pyrrolopyrrolone comme inhibiteurs d'elastase de neutrophiles.
EP0661972A4 (fr) Utilisation de la spiperone ou de derives de la spiperone comme agents immunodepresseurs.
IT1302243B1 (it) Sintesi dell'1,1,1,3,3-pentafluoropropano.
DZ2308A1 (fr) Procédés et intermédiaires pour la préparation de dérivés de chromanol substitués.
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
FI972306A0 (fi) Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BR9708595A (pt) Utilização de derivados de 2,5- di-hidroxibenzenossulfonicos
DE69610104D1 (de) Kondensierte thiazol-derivate, mit 5-ht-rezeptor affinität
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
TR199800068A3 (tr) Benzofenon türevlerinin hazirlanmasina yönelik metodlar.
FR2708604B1 (fr) Utilisation de dérivés de benzènesulfonyl-indole pour la préparation de médicaments.

Legal Events

Date Code Title Description
ST Notification of lapse